Use of a PPARalpha Agonist and Metformin for Decreasing the Serum Triglycerides
AssigneeFournier Laboratories Ireland Limited
InventorsJean-Louis Junien, Alan Edgar, Evelyne Chaput
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combined use of a PPARα agonist and metformin for decreasing serum triglycerides.
Claims14
A method of decreasing serum triglycerides consisting of administering to a patient in need thereof an effective dosage of a PPARα agonist and an effective dosage of metformin, wherein the PPARα agonist is selected from the group consisting of fenofibrate, fenofibric acid and pharmaceutically acceptable salts of fenofibric acid, wherein said effective dosage of the PPARα agonist and said effective dosage of metformin are effective for decreasing serum triglycerides.
A method of treating obesity consisting of administering to a patient in need thereof an effective dosage of a PPARα agonist and an effective dosage of metformin, wherein the PPARα agonist is selected from the group consisting of fenofibrate, fenofibric acid and a pharmaceutically acceptable salt of fenofibric acid, wherein said effective dosage of the PPARα agonist and said effective dosage of metformin are effective for the treatment of obesity.
Dependencies are inferred from the claim text.